Autopsy report · NCT05446168

Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation

“Withdrawal of funding”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 3 months before it stopped.
• 18 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Nicolaas Bohnen, MD, PhD

Sponsor type

University, hospital or other

Conditions

Parkinson Disease

Interventions

tributyrin

Participants

18

Sites

1

Countries

United States

Trials that died the same way

• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
  “Funding withdrawal” (98% match in meaning)
• Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
  “Withdrawal of funding support” (91% match in meaning)
• The Homeogenomic Trial
  “Funding withdrawn” (90% match in meaning)
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
  “funding was withdrawn” (85% match in meaning)
• Hydroxychloroquine Efficacy in Chronic Urticaria
  “withdrawn, not funded” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.